Total submissions: 35
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000112779 | SCV000244410 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-08-10 | reviewed by expert panel | curation | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 0.000000531 |
Labcorp Genetics |
RCV000049113 | SCV000077126 | benign | Hereditary breast ovarian cancer syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000034762 | SCV000167234 | benign | not provided | 2018-11-12 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 27153395, 22703879, 24055113, 19200354, 23867111, 21520273, 25637381, 21990134, 25782689, 15235020, 16014699, 21965345, 15307796, 15300854, 25823446, 26246475, 26332594, 33087888) |
Michigan Medical Genetics Laboratories, |
RCV000112779 | SCV000195886 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2014-11-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000162555 | SCV000212965 | benign | Hereditary cancer-predisposing syndrome | 2014-11-18 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Counsyl | RCV000112779 | SCV000220389 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2014-06-08 | criteria provided, single submitter | literature only | |
Institute for Biomarker Research, |
RCV000049113 | SCV000267857 | likely benign | Hereditary breast ovarian cancer syndrome | 2016-04-25 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000148400 | SCV000324818 | likely benign | Breast and/or ovarian cancer | 2022-11-15 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000157724 | SCV000538445 | uncertain significance | not specified | 2017-01-24 | criteria provided, single submitter | clinical testing | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: This variant has been reported in HGMD in 1 individual, showing that it leads to loss of expression of BRCA1. This variant is present in ExAC with a Max MAF of 0.04% (25/65600 chrs). It is classified in ClinVar with 3 stars as benign by 5 submitters (including expert panel ENIGMA), Likely benign by 3 submitters, and VUS by 3 submitters. |
Genetic Services Laboratory, |
RCV000157724 | SCV000593663 | likely benign | not specified | 2016-07-15 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000034762 | SCV000602736 | benign | not provided | 2023-03-31 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000162555 | SCV000683352 | benign | Hereditary cancer-predisposing syndrome | 2015-01-13 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000112779 | SCV001140623 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000112779 | SCV001280988 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
CHEO Genetics Diagnostic Laboratory, |
RCV000148400 | SCV001333444 | likely benign | Breast and/or ovarian cancer | 2021-06-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000034762 | SCV001501183 | likely benign | not provided | 2023-07-01 | criteria provided, single submitter | clinical testing | BRCA1: BP1, BS3:Supporting |
Sema4, |
RCV000162555 | SCV002537895 | likely benign | Hereditary cancer-predisposing syndrome | 2021-03-15 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV000157724 | SCV002551042 | benign | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002504870 | SCV002808838 | likely benign | Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 1; Pancreatic cancer, susceptibility to, 4; Fanconi anemia, complementation group S | 2022-03-22 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000112779 | SCV004818415 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2024-02-05 | criteria provided, single submitter | clinical testing | |
Biesecker Lab/Clinical Genomics Section, |
RCV000034762 | SCV000043184 | variant of unknown significance | not provided | 2012-07-13 | no assertion criteria provided | research | Converted during submission to Uncertain significance. |
Breast Cancer Information Core |
RCV000112779 | SCV000145673 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2002-05-29 | no assertion criteria provided | clinical testing | |
CSER _CC_NCGL, |
RCV000148400 | SCV000190099 | uncertain significance | Breast and/or ovarian cancer | 2014-06-01 | no assertion criteria provided | research | |
Knight Diagnostic Laboratories, |
RCV000112779 | SCV000493711 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-06-04 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001353473 | SCV000591299 | benign | Malignant tumor of breast | no assertion criteria provided | clinical testing | The BRCA1, p.Leu246Val variant was identified in 7 of 7716 proband chromosomes (frequency: 0.001) from individuals or families with breast and ovarian cancer (Akbari 2011, Capanu 2011, Diez 2003). The variant was also identified in dbSNP (ID: rs28897675) “With Uncertain significance allele”, with a minor allele frequency of 0.0002 (1000 Genomes Project), NHLBI Exome Sequencing Project (Exome Variant Server), Exome Aggregation Consortium (ExAC) database, LOVD, the ClinVar database (classified as a benign variant by the Invitae, GeneDx and Ambry genetics; classified as Likely benign by Counsyl; classified as Uncertain significance by BIC, by Biesecker Laboratory and by CSER_CC_NCGL), GeneInsight COGR database (1X, classified as “Benign” by a clinical laboratory), the BIC database (80X with unknown clinical importance), and UMD (17X as a neutral variant). In UMD the variant was identified with a co-occurring pathogenic BRCA1 and BRCA2 variants (BRCA1 c.3901_3902delAG (p.Ser1301X); BRCA2 c.5984dup (p.Asn1995delinsLys)), increasing the likelihood that the p.Leu246Val variant does not have clinical significance. This variant was identified in the 1000 Genomes Project in 1 of 5000 chromosomes (frequency: 0.0002), Exome Variant Server project in 3 of 8600 European American alleles, the Exome Aggregation Consortium (ExAC) database (released Jan 13, 2015) in 26 of 76950 chromosomes (frequency: 0.0003) from a population of European (Non-Finnish) and Latino individuals, increasing the likelihood this could be a low frequency benign variant. The p.Leu246 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein. However, this information is not predictive enough to rule out pathogenicity. In addition, the Val residue is also present in opossum, which would increase the likelihood this variant may not have functional significance. The variant occurs outside of the splicing consensus sequence and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. RNA based analysis by Sharp (2004) suggest that the mutation is associated with either constitutive skipping of exon 11, or monoallelic BRCA1 expression. However, two functional studies characterized the variant as neutral (Abkevich 2004, Gómez García 2009). In addition, this variant have been observed with two or more known deleterious mutations, increasing the likelihood this variant does not have clinical significance (Tavtigian 2006, Judkins 2005). In summary, based on the above information, this variant meets our laboratory's criteria to be classified as benign. | |
Diagnostic Laboratory, |
RCV000112779 | SCV000733666 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion criteria provided | clinical testing | ||
Mayo Clinic Laboratories, |
RCV000034762 | SCV000778774 | likely benign | not provided | 2017-04-03 | no assertion criteria provided | clinical testing | |
True Health Diagnostics | RCV000162555 | SCV000787913 | likely benign | Hereditary cancer-predisposing syndrome | 2017-10-25 | no assertion criteria provided | clinical testing | |
Foulkes Cancer Genetics LDI, |
RCV000148400 | SCV000863627 | uncertain significance | Breast and/or ovarian cancer | 2002-03-15 | no assertion criteria provided | clinical testing | |
Laboratory of Diagnostic Genome Analysis, |
RCV000157724 | SCV001799917 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics Laboratory, |
RCV000157724 | SCV001905687 | benign | not specified | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000157724 | SCV001931498 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000157724 | SCV001953037 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000157724 | SCV001972436 | benign | not specified | no assertion criteria provided | clinical testing | ||
BRCAlab, |
RCV000112779 | SCV004244149 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2020-03-02 | no assertion criteria provided | clinical testing |